Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
The endocrine effects of induction of ovulation with menotropins were studied in 43 patients: 11 with hypothalamic amenorrhea and 32 with the polycystic ovary syndrome. Patients with polycystic ovary syndrome had higher base-line values of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), 17 beta-estradiol, dehydroepiandrosterone sulfate, testosterone, and a higher testosterone-free index than those with hypothalamic amenorrhea. During treatment with menotropins, patients with polycystic ovary syndrome had higher values of serum LH, prolactin, dehydroepiandrosterone sulfate, testosterone, percent free testosterone, testosterone-free index, and body weight than those with hypothalamic amenorrhea; serum FSH, dose of menotropins per kilogram body weight, and total follicular volume were higher in patients with hypothalamic amenorrhea than in those with polycystic ovary syndrome. Multiple linear regression after log transformation demonstrated that the testosterone-free index was predicted statistically by total ovarian volume and dehydroepiandrosterone sulfate and that serum 17 beta-estradiol was predicted statistically by total ovarian volume and testosterone-free index. Adding dexamethasone to menotropins in six patients with polycystic ovary syndrome produced significant decreases in 17 beta-estradiol, dehydroepiandrosterone sulfate, testosterone, and testosterone-free index. Higher concentrations of endogenous serum LH and dehydroepiandrosterone sulfate in patients with polycystic ovary syndrome in comparison with those with hypothalamic amenorrhea were associated with higher concentrations of serum testosterone, a lower total follicular volume, and an effective response to menotropins at a lower serum FSH and a lower dose of menotropins per kilogram body weight. These data suggest that serum dehydroepiandrosterone sulfate may be a precursor for ovarian steroidogenesis.
Haning
R V
RV
Austin
C W
CW
Carlson
I H
IH
Kuzma
D L
DL
Zweibel
W J
WJ
D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000568:Amenorrhea / Q000188:drug therapy; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000097:blood / Q000502:physiology; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone / Q000494:pharmacology; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000494:pharmacology*; D010053:Ovary / Q000378:metabolism*; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D008596:Menotropins; D003907:Dexamethasone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone